Revolution Medicines Inc. (RVMD)
NASDAQ: RVMD
· Real-Time Price · USD
38.95
-0.82 (-2.06%)
At close: Sep 04, 2025, 3:59 PM
38.95
0.00%
After-hours: Sep 04, 2025, 04:37 PM EDT
-2.06% (1D)
| Bid | 36.58 |
| Market Cap | 7.28B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -812.06M |
| EPS (ttm) | -4.52 |
| PE Ratio (ttm) | -8.62 |
| Forward PE | -6.94 |
| Analyst | Buy |
| Ask | 41 |
| Volume | 1,681,244 |
| Avg. Volume (20D) | 2,240,375 |
| Open | 39.58 |
| Previous Close | 39.77 |
| Day's Range | 38.49 - 39.58 |
| 52-Week Range | 29.17 - 62.40 |
| Beta | 1.16 |
About RVMD
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RVMD
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RVMD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Revolution Medicines Inc. is scheduled to release its earnings on
Nov 5, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+5.71%
Revolution Medicines shares are trading higher aft...
Unlock content with
Pro Subscription
4 months ago
+11.29%
Revolution Medicines shares are trading higher after Oppenheimer raised its price target on the stock from $70 to $75.
2 weeks ago · https://thefly.com
Piper starts Revolution Medicines at Overweight on daraxonrasib potentialPiper Sandler analyst Kelsey Goodwin last night initiated coverage of Revolution Medicines with an Overweight rating and $75 price target. The firm believes the stock's value will be driven by confide...
4 weeks ago · seekingalpha.com
Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call TranscriptRevolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Anthony Mancini - Chief Global Commercialization Officer Jack Anders - Chief F...
